Contact UsProstate Cancer FoundationAbout Prostate Cancer
Donate NowSubscribe Now
   
The Safeway Foundation $1 Million Matching Grant Challenge

About PCF

Prostate Cancer Research

Join the Fight


Obesity May Interfere with Prostate Cancer Screen
Findings suggest that because obese men's PSA levels tend to be relatively low in general, some cancers may be missed or not detected promptly

Thursday, June 26 (Reuters Health) - The test commonly used to screen men for prostate cancer may be more likely to miss tumors in obese men, a new study suggests.

In a study of 535 men in a free prostate cancer screening program, researchers found that obese men were more likely to have relatively low levels of prostate specific antigen (PSA), even when their prostate findings were abnormal.

PSA levels in the blood typically rise when a man has prostate cancer, so PSA testing is often used to screen for the disease. Men with a high PSA level can then have further testing to get a definitive diagnosis.

The new findings, published in the journal Urology, suggest that because obese men's PSA levels tend to be relatively low in general, some cancers may be missed or not detected promptly.

The generally lower PSA values in heavy men may be the result of a "dilution" effect, according to Dr. Stephen J. Freedland, of Duke University School of Medicine in Durham, North Carolina.

"Obese men have lower PSA values likely due to excess blood volume," Freedland, the senior investigator on the study, told Reuters Health.

"Thus, when interpreting a PSA value in an obese man," Freedland said, "we should adjust the value we call 'abnormal' downwards to reflect this diluted PSA measurement. If we do not, we may be missing cancers in obese men."

Of the men in his team's study, 73 percent were overweight or obese. Compared with their normal-weight counterparts, overweight men had 5 percent lower PSA value, on average. For mildly obese men the difference was 14 percent, and in moderately and severely obese men, the values were 29 percent lower.

"The current data," the researchers conclude, "suggest that the PSA cut-points used to recommend biopsy need to be adjusted for the degree of obesity."

SOURCE: Urology, May 2008.

Reuters

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Would you like to receive prostate cancer news by email? Subscribe to NewsPulse

Prostate Cancer Facts | About the Prostate | Risk Factors | Symptoms | PSA & DRE Screening | Diagnosis | Treatment | Nutrition | Personal Stories | Clinical Trials

Home | About PCF | Research| Join the Fight | Events | Publications | Press | Contact Us | Site Map | Privacy Policy | Terms of Use

1250 Fourth Street | Santa Monica, CA 90401| p: 1.800.757.CURE (2873)| f: 310.570.4701
info@pcf.org